BRCA1 and pancreatic neoplasm: Genetic testing has also become more important for pancreatic cancer patients, as those having BRCA1/2-mutant tumors are predicted to exhibit increased therapeutic sensitivity to platinum-containing therapeutic agents and inhibitors of poly-(ADP-ribose)-polymerase (PARP) [18].